The target is the immune attack on myelin.
Multiple sclerosis is an immune-mediated disease: the immune system attacks the myelin sheath that insulates the nerves of the brain and spinal cord, and each lesion interrupts the signals those nerves carry. Mesenchymal stem cells are delivered into the bloodstream by IV infusion, where they promote regulatory T-cells and shift the immune balance away from the inflammatory cell populations that drive demyelination. This therapy is used alongside the disease-modifying treatment plan from your neurologist — never in place of it.
The MS protocol uses 100 million Wharton’s jelly UC‑MSCs. The infusion takes 60 to 90 minutes, and you leave the clinic the same day. Intrathecal delivery — into the spinal fluid — exists for selected cases and is scoped only by the physician after record review.
The MS forms and demyelinating conditions we treat.
Each form, and every protocol we run for it. The final prescription is always the physician's, after your records, relapse history, and imaging are reviewed.
MS runs on the high-dose protocol.
Every dose is expanded from Wharton's jelly umbilical-cord tissue, tested for viability, and flown in the day of your treatment.
100M
cells in the standard MS protocol — systemic IV delivery, the route used in the majority of published MSC trials in MS.
Intrathecal
delivery into the spinal fluid brings cells closer to central-nervous-system lesions. Offered only where the physician judges the case supports it.
ISO‑certified
GMP laboratory. Each dose is released only after sterility, identity, and viability verification.
What happens after the infusion.
Tap a step to follow the cells from the IV line into circulation.
What the response looks like.
A typical MS protocol timeline, measured against your own baseline. Your physician tailors it to your form of MS and your case.
Day 0
Monitored IV infusion
60–90 minutes in a private suite. Most patients report nothing beyond mild transient fatigue or flushing in the first 24 hours. You continue your disease-modifying therapy unless your own neurologist directs otherwise.
Weeks 2–8
Early signals
Where there is a response, patients often notice it first as reduced fatigue or spasticity. Early changes tend to be modest, and some patients notice nothing in this window.
Months 3–6
Primary reassessment
Structured re-measurement against your baseline — relapse activity, disability scores such as EDSS, and MRI where your neurologist orders it. Ideally shared with your treating team.
Beyond 6 months
Durability & booster review
Any change to disease-modifying therapy is your prescribing neurologist's decision, based on measured disease control. A booster infusion is typically considered at 9 to 12 months.
The evidence, briefly.
Three anchor findings from the peer-reviewed MS literature — including the one that missed its endpoint.
RCT
Randomized, sham-controlled trial in 48 patients with active progressive MS: intrathecal and IV MSC treatment produced significantly fewer patients with treatment failure than sham, with the strongest effects intrathecally.
Petrou P, et al. Brain, 2020.
UC‑MSC
Phase 1/2 study of intravenous umbilical-cord MSCs — the cell type we use — in MS: the protocol was safe and well tolerated over one year of follow-up, with symptom and quality-of-life improvements reported; the study was uncontrolled.
Riordan NH, et al. J Transl Med, 2018.
MESEMS
The largest randomized, double-blind trial to date (144 patients, 9 countries): IV bone-marrow MSCs were safe but did not reduce new MRI lesion activity — the honest ceiling on what a single IV infusion has been shown to do.
Uccelli A, et al. Lancet Neurol, 2021.
The MS evidence deserves to be read exactly as it stands. Safety is consistently supported across trials and meta-analyses of MSC infusion. Efficacy is genuinely mixed: the single-center randomized trial from Hadassah (Petrou 2020) found meaningful benefit, strongest with intrathecal delivery, while the multi-center MESEMS trial (Uccelli 2021) found no effect on MRI lesion activity from a single IV dose. Cell source, dose, and route likely matter, and none of this is definitive or a guarantee of any individual result. This therapy is an adjunct to specialist-led neurology care, not a replacement for it — stopping disease-modifying therapy to pursue cell therapy is a reason we would advise against proceeding. Not FDA-approved for these uses; provided in México under COFEPRIS after individual physician review of your diagnosis, relapse history, imaging, and current treatment.
